DFV890

A Phase 1b, Open Label, Multi-center, Dose Optimization and Dose Expansion Study to Assess the Safety and Efficacy of DFV890 in Adult Patients With Myeloid Diseases

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
80 patients (estimated)
Sponsors
Novartis
Tags
NLRP3 Inhibitor
Trial Type
Treatment
Last Update
2 months ago
SparkCures ID
1752
NCT Identifier
NCT05552469

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.